Evidence map›Paper›PMID 27773929›Full record

Trial reportLeukemia2017

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

A Tefferi, H K Al-Ali, G Barosi, T Devos, H Gisslinger, Q Jiang, J-J Kiladjian, R Mesa, F Passamonti, M F McMullin and 7 more

Erratum issuedOpen access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Myelofibrosis.Blood · 2023
    Review
  8. New approaches to tackle cytopenic myelofibrosis.Hematology. American Society of Hematology. Education Program · 2022
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Lowering the boom on lower-risk myelodysplastic syndromes.Hematology. American Society of Hematology. Education Program · 2019
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 8 countries.

A TefferiDivision of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA.
H K Al-AliUniversitätsklinikum Leipzig, Leipzig, Germany.
G BarosiFondazione IRCCS Policlinico S Matteo, Pavia, Italy.
T DevosUniversitaire Ziekenhuizen, Leuven, Belgium.
H GisslingerMedizinische Universität Wien, Vienna, Austria.
Q JiangPeking University People's Hospital, Beijing, China.
J-J KiladjianHôpital Saint-Louis, Paris, France.
R MesaMayo Clinic, Scottsdale, AZ, USA.
F PassamontiUniversity of Insubria, Varese, Italy.
M F McMullinDepartment of Haematology, Queen’s University, Belfast, UK.
V RibragGustave Roussy, Université Paris-Saclay, Saint-Aubin, France.
G SchillerDivision of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
A M VannucchiCentro Ricerca e Innovazione Malattie Mieloproliferative-CRIMM, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
D ZhouPeking Union Medical College Hospital, Beijing, China.
D ReiserCelgene Corporation, Summit, NJ, USA.
J ZhongCelgene Corporation, Summit, NJ, USA.
R P GaleCelgene Corporation, Summit, NJ, USA.
Mayo Clinic in Arizona · USChinese Academy of Medical Sciences & Peking Union Medical College · CNPeking University · CNUniversitair Ziekenhuis Leuven · BEUniversity of California, Los Angeles · USUniversity of Insubria · ITImperial College London · GBUniversity Hospital Leipzig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RBC-transfusion dependence is common in persons with myeloproliferative neoplasm (MPN)-associated myelofibrosis. The objective of this study was to determine the rates of RBC-transfusion independence after therapy with pomalidomide vs placebo in persons with MPN-associated myelofibrosis and RBC-transfusion dependence. Two hundred and fifty-two subjects (intent-to-treat (ITT) population) including 229 subjects confirmed by central review (modified ITT population) were randomly assigned (2:1) to pomalidomide or placebo. Trialists and subjects were blinded to treatment allocation. Primary end point was proportion of subjects achieving RBC-transfusion independence within 6 months. One hundred and fifty-two subjects received pomalidomide and 77 placebo. Response rates were 16% (95% confidence interval (CI), 11, 23%) vs 16% (8, 26%; P=0.87). Response in the pomalidomide cohort was associated with ⩽4 U RBC/28 days (odds ratio (OR)=3.1; 0.9, 11.1), age ⩽65 (OR=2.3; 0.9, 5.5) and type of MPN-associated myelofibrosis (OR=2.6; 0.7, 9.5). Responses in the placebo cohort were associated with ⩽4 U RBC/28 days (OR=8.6; 0.9, 82.3), white blood cell at randomization >25 × 10

Indexed as

AdultAgedAged, 80 and overBiomarkersErythrocyte TransfusionFemaleHumansImmunologic FactorsMaleMiddle AgedMyeloproliferative DisordersPhenotypePrimary MyelofibrosisThalidomideTreatment OutcomeWorkflowBiomarkersImmunologic FactorspomalidomideThalidomide

Identifiers

PMID27773929
PMCPMC5383927
OpenAlexW2534149640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.